Goldman Sachs’s C4 Therapeutics CCCC Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.26M | Buy |
880,258
+257,538
| +41% | +$368K | ﹤0.01% | 3701 |
|
|
2025
Q1 | $996K | Buy |
622,720
+49,065
| +9% | +$78.5K | ﹤0.01% | 3812 |
|
|
2024
Q4 | $2.07M | Buy |
573,655
+67,803
| +13% | +$244K | ﹤0.01% | 3458 |
|
|
2024
Q3 | $2.88M | Sell |
505,852
-231,983
| -31% | -$1.32M | ﹤0.01% | 3117 |
|
|
2024
Q2 | $3.41M | Sell |
737,835
-543,407
| -42% | -$2.51M | ﹤0.01% | 2880 |
|
|
2024
Q1 | $10.5M | Buy |
1,281,242
+1,167,729
| +1,029% | +$9.54M | ﹤0.01% | 2014 |
|
|
2023
Q4 | $641K | Sell |
113,513
-105,210
| -48% | -$594K | ﹤0.01% | 3825 |
|
|
2023
Q3 | $407K | Sell |
218,723
-11,843
| -5% | -$22K | ﹤0.01% | 3968 |
|
|
2023
Q2 | $634K | Sell |
230,566
-115,017
| -33% | -$316K | ﹤0.01% | 3857 |
|
|
2023
Q1 | $1.09M | Buy |
345,583
+61,631
| +22% | +$194K | ﹤0.01% | 3611 |
|
|
2022
Q4 | $1.68M | Sell |
283,952
-136,891
| -33% | -$808K | ﹤0.01% | 3390 |
|
|
2022
Q3 | $3.69M | Buy |
420,843
+289,119
| +219% | +$2.54M | ﹤0.01% | 2892 |
|
|
2022
Q2 | $993K | Buy |
131,724
+11,935
| +10% | +$90K | ﹤0.01% | 3938 |
|
|
2022
Q1 | $2.91M | Sell |
119,789
-105,059
| -47% | -$2.55M | ﹤0.01% | 3274 |
|
|
2021
Q4 | $7.24M | Sell |
224,848
-39,116
| -15% | -$1.26M | ﹤0.01% | 2519 |
|
|
2021
Q3 | $11.8M | Buy |
263,964
+33,001
| +14% | +$1.47M | ﹤0.01% | 2134 |
|
|
2021
Q2 | $8.74M | Buy |
+230,963
| New | +$8.74M | ﹤0.01% | 2352 |
|
|
2021
Q1 | – | Sell |
-12,624
| Closed | -$418K | – | 5250 |
|
|
2020
Q4 | $418K | Buy |
+12,624
| New | +$418K | ﹤0.01% | 3917 |
|